Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA, overvalued on P/FC.
Target Price
The average target price of XFOR is 9.1 and suggests 167% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell